<DOC>
	<DOC>NCT00394186</DOC>
	<brief_summary>This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.</brief_summary>
	<brief_title>A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Solabegron</mesh_term>
	<mesh_term>Adrenergic Agonists</mesh_term>
	<criteria>Diagnosis of IBS which meets the Rome II criteria, screening pain score to be &gt; 1.5 (0= no pain, 4 = very severe pain) Subjects not meeting the Rome II criteria for the diagnosis of IBS Subjects with no stool for 7 days during the screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>GW427353</keyword>
	<keyword>b3-Adrenergic Receptor Agonist</keyword>
	<keyword>Irritable Bowel Syndrome (IBS)</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>